No profile data available.
Puma Biotechnology, Inc. (PBYI) is a healthcare company in the breast cancer treatment drugs industry, based in Los Angeles, United States, with about 179 full-time employees.
It reported revenue of $228.37 million for fiscal year 2025, down 0.9% from fiscal year 2024, and net income of $31.11 million. Its market capitalization was $531.17 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
Puma Biotechnology reported $228.37 million in revenue for fiscal year 2025, down 0.9% from $230.47 million in fiscal year 2024.
$531.17 million as of October 9, 2026.
Listed companies of a similar size in the same industry (breast cancer treatment drugs) include Celcuity Inc. (CELC), Olema Pharmaceuticals, Inc. (OLMA), Greenwich LifeSciences, Inc. (GLSI), Odonate, Inc. (ODTC).